Search hospitals > Arkansas > Little Rock

Veterans Affairs Medical Center - Little Rock (McClellan)

Claim this profile
Little Rock, Arkansas 72205
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Leukemia
111 reported clinical trials
7 medical researchers
Photo of Veterans Affairs Medical Center - Little Rock (McClellan) in Little RockPhoto of Veterans Affairs Medical Center - Little Rock (McClellan) in Little RockPhoto of Veterans Affairs Medical Center - Little Rock (McClellan) in Little Rock

Summary

Veterans Affairs Medical Center - Little Rock (McClellan) is a medical facility located in Little Rock, Arkansas. This center is recognized for care of Skin Cancer, Lung Cancer, Non-Small Cell Lung Cancer, T-Lymphoblastic Leukemia/Lymphoma, Leukemia and other specialties. Veterans Affairs Medical Center - Little Rock (McClellan) is involved with conducting 111 clinical trials across 134 conditions. There are 7 research doctors associated with this hospital, such as Rangaswamy Govindarajan, Ryan Dare, MD, Matt Burns, MD, and Barry Uretsky, MD.

Area of expertise

1Skin Cancer
Global Leader
Veterans Affairs Medical Center - Little Rock (McClellan) has run 19 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
Veterans Affairs Medical Center - Little Rock (McClellan) has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage III

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Little Rock (McClellan)

Multiple Myeloma
Lung Cancer
Skin Cancer
Plasma Cell Neoplasm
ALK Gene Rearrangement
Atherosclerosis
Diabetic Kidney Disease
Cutaneous Melanoma
Liver Disease
Non-Small Cell Lung Cancer
Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Drug Combinations

for Multiple Myeloma

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.
Recruiting2 awards Phase 321 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Veterans Affairs Medical Center - Little Rock (McClellan)?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security